How Semaglutide, Tirzepatide, and Next-Gen Peptides Are Transforming Diabetes and Obesity Treatment

What the researchers found

Semaglutide (available as weekly injection or daily pill) and tirzepatide (weekly injection targeting both GLP-1 and GIP receptors) have achieved HbA1c reductions of over 2% and body weight reductions of over 10% in type 2 diabetes patients. In non-diabetic obese individuals treated at higher doses, weight loss exceeded 15%.

Emerging evidence shows cardio-protective and potentially reno-protective effects. Next-generation therapies in early clinical development — retatrutide (triple GLP-1/GIP/glucagon agonist) and CagriSema (semaglutide + amylin analogue cagrilintide) — have demonstrated even stronger efficacy. Gastrointestinal side effects are generally mild-to-moderate and transient, though they cause some patients to discontinue treatment.

Why it matters

Incretin-based peptide therapies represent the most significant advance in diabetes and obesity treatment in decades. The ability to achieve double-digit weight loss percentages and substantial blood sugar control with a single weekly injection is reshaping clinical practice. The emergence of dual and triple agonists suggests we're only at the beginning of what peptide-based therapies can achieve for metabolic diseases.

How the study worked

This is a narrative review of recent large clinical trials involving incretin-based peptide therapies for type 2 diabetes and obesity, synthesizing efficacy, safety, and emerging data on cardiovascular and renal outcomes across multiple drug classes.

What this study cannot tell us

As a narrative review, this article synthesizes existing trial data rather than presenting new primary research. Most large trials have been relatively short-term (1-2 years), and the long-term safety and durability of weight loss after treatment cessation remain uncertain. Cost and access barriers limit the real-world impact of these therapies. The review primarily covers completed trials and may not capture the most recent pipeline developments.

How to read the evidence

This review synthesizes data from multiple large randomized controlled trials — the highest level of clinical evidence. The reviewed therapies have strong evidence supporting their efficacy and have received regulatory approval based on these trials.

When this study was published

Published in early 2024, this review captures the state of incretin therapy through the major semaglutide and tirzepatide trials. The field has continued to advance rapidly since publication, with new data on retatrutide and CagriSema emerging.

The bigger picture

The incretin peptide revolution is one of the most important stories in modern medicine. Starting with exenatide and accelerating through semaglutide and tirzepatide, peptide-based therapies have evolved from modest glucose-lowering agents to transformative treatments that dramatically reduce weight, protect the heart, and may benefit the kidneys. With triple agonists and combination therapies on the horizon, peptide medicine is entering a golden age for metabolic disease.

Questions still open

• Will weight loss be maintained long-term after stopping incretin peptide therapies, or will patients regain weight?
• How do the cardiovascular benefits of tirzepatide compare to those established for semaglutide?
• Will triple agonists like retatrutide prove safe enough for widespread use given their more aggressive pharmacology?

Common questions

Read the original research

Recent advances in peptide-based therapies for obesity and type 2 diabetes.

Peptides, 173, 171149

Citation

Bailey, Clifford J; Flatt, Peter R; Conlon, J Michael. (2024). Recent advances in peptide-based therapies for obesity and type 2 diabetes.. Peptides, 173, 171149. https://doi.org/10.1016/j.peptides.2024.171149